甲氨蝶呤联合叶酸治疗风湿病患者血细胞减少发生率的荟萃分析
该系统综述与荟萃分析纳入30项随机双盲对照试验、共3858例类风湿关节炎患者,评估甲氨蝶呤联合叶酸治疗相关贫血、白细胞减少、中性粒细胞减少和血小板减少的发生率。结果显示贫血发生率2.55%、白细胞减少1.17%、中性粒细胞减少1.77%、血小板减少0.19%,严重血细胞减少罕见。
要点
- 低剂量甲氨蝶呤联合叶酸治疗的类风湿关节炎患者血细胞减少发生率较低。
- 贫血发生率2.55%,白细胞减少1.17%,中性粒细胞减少1.77%,血小板减少0.19%。
- 严重贫血4例、严重中性粒细胞减少3例,无严重白细胞减少、血小板减少或全血细胞减少。
核心结论
- 在补充叶酸的类风湿关节炎患者中,低剂量甲氨蝶呤导致的血细胞减少是不常见的不良反应。
研究设计与样本
- 系统检索MEDLINE、PubMed和EMBASE至2016年8月,纳入30项报告血液学不良事件的随机双盲对照试验,共3858例类风湿关节炎患者。
主要发现
- 贫血发生率2.55%(95%CI 0.60-5.47%),白细胞减少1.17%(95%CI 0.16-2.80%),中性粒细胞减少1.77%(95%CI 0.33-4.00%),血小板减少0.19%(95%CI 0.00-0.86%)。
- 报告严重贫血4例、严重中性粒细胞减少3例,无严重白细胞减少、严重血小板减少或全血细胞减少病例。
关键数值与推荐
- 贫血评估基于17项试验共2032例,白细胞减少基于17项试验共2220例,中性粒细胞减少基于16项试验共2202例,血小板减少基于12项试验共1507例。
临床怎么用
- 对于使用低剂量甲氨蝶呤并补充叶酸的类风湿关节炎患者,血细胞减少风险较低,但仍需按临床常规监测血常规。
局限性
- 仅纳入类风湿关节炎患者,所有研究均为双盲随机对照试验,需进一步研究以获得更精确的估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To conduct a systematic literature review and meta-analysis to estimate the incidence of anaemia, leucopoenia, neutropenia and thrombocytopenia associated with MTX plus folic acid among patients with rheumatic diseases. METHODS: We searched MEDLINE, PubMed and EMBASE through August 2016 for all randomized controlled clinical trials with a MTX monotherapy arm. We excluded randomized controlled clinical trials for cancer and included only double-blind studies that reported on haematologic adverse events. Studies were excluded if patients did not receive folic acid or leucovorin supplementation. Full text articles were assessed by two independent reviewers. Incidence estimates were calculated using random-effects models. RESULTS: Of 1601 studies identified, 30 (1.87%) were included, representing 3858 patients; all had RA. Seventeen trials reported on anaemia (n = 2032), 17 reported on leucopoenia (n = 2220), 16 reported on neutropenia (n = 2202) and 12 reported on thrombocytopenia (n = 1507). The incidence for any anaemia was 2.55% (95% CI 0.60-5.47%), any leucopoenia 1.17% (95% CI 0.16-2.80%), any neutropenia 1.77% (95% CI 0.33-4.00%), and any thrombocytopenia 0.19% (95% CI 0.00-0.86%). Four cases of severe anaemia were reported, as defined by authors, along with three cases of severe neutropenia. No cases of severe leucopoenia, severe thrombocytopenia or pancytopenia were reported. CONCLUSION: Cytopenias are an uncommon side effect of low-dose MTX with folic acid supplementation among RA patients. Further research is needed to reach a more precise estimate.
引用
- Vanni KMM, Lyu H, Solomon DH, et al. Cytopenias among patients with rheumatic diseases using methotrexate: a meta-analysis of randomized controlled clinical trials. Rheumatology (Oxford). 2020. PMID: 31504937. doi:10.1093/rheumatology/kez343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。